Skip to Content
by Leigh MacMillan | Posted on Wednesday, Dec. 26, 2012 — 8:00 AM
Heart valve disease has few non-surgical therapeutic options. To develop strategies for treating and preventing heart valve disease, W. David Merryman, Ph.D., assistant professor of Biomedical Engineering, and colleagues are studying the cellular signaling that leads to calcification (hardening) of the aortic valve.
Previous studies have shown that the TGF-beta1 signaling pathway activates a process in aortic valve interstitial cells that is thought to cause calcification and heart valve disease. The cell surface serotonin-2B receptor also activates this process. Now, in the November Journal of Molecular and Cellular Cardiology, the investigators report that blocking the serotonin-2B receptor (with an inhibitor drug) prevents activation of aortic valve cells and formation of calcific nodules in a cell culture system. They further show that inhibition of the serotonin-2B receptor blocks the so-called “non-canonical” TGF-beta1 signaling pathway, but not the “canonical” pathway.
The findings demonstrate that non-canonical TGF-beta1 signaling leads to pathologic activation of aortic valve cells and suggest that blocking the serotonin-2B receptor may provide a novel therapeutic approach for preventing heart valve disease.
Leigh MacMillan, (615) 322-4747
Health and Medicine, Reporter, Research AHA, Aliquots, American Heart Association, aortic stenosis, cardiac, David Merryman, heart, heart valve, Journal of Molecular and Cellular Cardiology, journal publication, NHLBI, NIH, NSF, Reporter Dec 21 2012, serotonin, TGF-beta
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: